Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

Howard L. Ritter, Richard J. Gralla, Stephen W. Hall, J. K. Wada, Carl Friedman, Linda Hand, David Fitts

Research output: Contribution to journalArticle

20 Scopus citations


The safety and efficacy of granisetron (10 μg/kg and 40 μg/kg) were evaluated during a second (n = 393) and third (n = 200) cycle of chemotherapy in this multicenter, double-blind, randomized, parallel-group study. Granisetron was administered as a single intravenous dose before the start of cisplatin chemotherapy (≤60 mg/m2). Total control (no vomiting, no retching, no nausea, and no use of antiemetic rescue medications) after the first 24 hr following chemotherapy was achieved in 40% and 49% of patients in cycles 2 and 3, respectively, for the 10 μg/kg group, and in 42% and 38% of patients in Cycles 2 and 3, respectively, for the 40μg/kg group. Both dose levels of granisetron were well tolerated. The results demonstrate comparable efficacy between the 10 μg/kg and 40 μg/kg doses of granisetron in preventing cause and vomiting during repeat cycles of high-dose cisplatin- based chemotherapy. The results of this study show that granisetron 10 μg/kg is safe and well tolerated, and remains effective with repeat cycle use.

Original languageEnglish (US)
Pages (from-to)87-93
Number of pages7
JournalCancer Investigation
Issue number2
Publication statusPublished - Jan 1 1998


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this